Farewell to Chris Richardson

Chris Richardson joined the lab as a Postdoctoral Fellow in July 2014 and made huge advances in human gene editing. He developed new ways to improve NHEJ and HDR, plus discovered out that genome editing in human cells works via the Fanconi Anemia Pathway. Three major first author papers in three years – not bad! Chris will be joining Spotlight Therapeutics as a Group Leader, and may have some additional career news to share soon. We wish you success in all your future endeavors!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

June 17, 2021

Congratulations to Eric and John on the EMBO fellowships!

We are excited to share the news that Eric Aird and John Fielden were both awarded EMBO long-term fellowships, which support excellent postdoctoral researchers...

April 11, 2021

Welcome to Xiaojing

Xiaojing received her Ph.D. from Weill Cornell Graduate School of Medical Science in 2020, working with Dr. Scott Keeney on the mechanism to regulate meiotic...

April 11, 2021

Welcome to Danielle

Danielle received her Ph.D. from Brandeis University in 2021 where she worked with Dr. James Haber to characterize the mechanisms of gene editing via single...

News Archive

Tweets